Kelly C. Hewitt
Rating: 4.9 of 5
( out of 35 reviews )

Kelly C. Hewitt, MD, FACS

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital North

2K, Breast Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
801-587-4241
Get Directions

  • Kelly Hewitt, MD, FACS, is a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute specializing in the surgical care of malignant and benign breast disease and management and surgical care of ductal carcinoma in situ (DCIS).

    Dr. Hewitt received her undergraduate degree from Johns Hopkins University and went to Georgetown University for her medical degree. She then completed her surgical residency at the University of Utah and received fellowship training in breast surgical oncology at the University of California, San Francisco.

    Dr. Hewitt’s research interests include minimizing overdiagnosis and overtreatment of DCIS and investigating ways to understand which patients require surgery and who may be managed with active surveillance. She is also involved in clinical trials for early-stage breast cancer and improving access to care throughout the Mountain West. She is a national co-principal investigator for the DCIS:RECAST clinical trial.

    Dr. Hewitt strives to provide personalized surgical care by working closely with her patients. She helps them understand their condition and treatment options, collaborating to create a surgical plan that aligns with their personal goals while ensuring optimal care for their disease.

    In her free time, Dr. Hewitt enjoys trail running, mountain biking, snowboarding, curling up on the couch with a good book, and attending her kids’ activities.

    Specialties

    Board Certification

    American Board of Surgery

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 35 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    August 29, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    She was very informative. Helped in making my plan for treatment. Personable. Easy to trust her judgment. She showed empathy.

    August 21, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Hewitt was very kind and open for any questions.

    August 17, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Great review of what was happening and possible ways of treatment

    August 15, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Hewitt took her time to explain everything and made me very comfortable

    August 07, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very very good at what she does.

    May 24, 2025
    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Dr. Hewitt is amazing and really cares about her patients.

    May 03, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I love the way Dr. Hewitt took the time to fully explain the process of what I'll be going through. She was attentive and very trauma informed. She listened carefully and made sure I understood what was being explained to me. I truly appreciate her.

    April 07, 2025
    SOUTH JORDAN HEALTH CENTER
    Rating: 5 out of 5

    Professional. Plan still in progress due to testing results to be scheduled this week.

    April 03, 2025
    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Hewitt is kind, compassionate & extremely knowledgeable. She made me feel comfortable right from the start. She wants what's best for her patients. She explains things in terminology that you can understand. I look forward to having her treat me.

  • Kelly Hewitt, MD, FACS, is a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute specializing in the surgical care of malignant and benign breast disease and management and surgical care of ductal carcinoma in situ (DCIS).

    Dr. Hewitt received her undergraduate degree from Johns Hopkins University and went to Georgetown University for her medical degree. She then completed her surgical residency at the University of Utah and received fellowship training in breast surgical oncology at the University of California, San Francisco.

    Dr. Hewitt’s research interests include minimizing overdiagnosis and overtreatment of DCIS and investigating ways to understand which patients require surgery and who may be managed with active surveillance. She is also involved in clinical trials for early-stage breast cancer and improving access to care throughout the Mountain West. She is a national co-principal investigator for the DCIS:RECAST clinical trial.

    Dr. Hewitt strives to provide personalized surgical care by working closely with her patients. She helps them understand their condition and treatment options, collaborating to create a surgical plan that aligns with their personal goals while ensuring optimal care for their disease.

    In her free time, Dr. Hewitt enjoys trail running, mountain biking, snowboarding, curling up on the couch with a good book, and attending her kids’ activities.

    Board Certification and Academic Information

    Academic Departments Surgery -Associate Professor (Clinical)
    Academic Divisions Surgical Oncology
    Board Certification
    American Board of Surgery

    Education history

    Fellowship Breast Surgical Oncology - University of California, San Francisco School of Medicine Fellow
    Residency General Surgery - University of Utah School of Medicine Resident
    Professional Medical Medicine - Georgetown University School of Medicine M.D.
    Undergraduate Biology - Johns Hopkins University B.A.

    Selected Publications

    Journal Article

    1. Kuo MC, Sims J, Solis OK, Meszoely IM, Sweeting RS, Grau AM, Hewitt KC, Kauffmann RM, Kelley MC, McCaffrey RL (2024). Disease recurrence in patients undergoing mastectomy for ductal carcinoma in situ. Breast Cancer Res Treat. (Read full publication)
    2. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, ISPY2 Locoregional Working Group, Boughey JC (2024). ASO Visual Abstract: Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy-Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. (Read full publication)
    3. Sols O, Addae J, Sweeting R, Meszoely I, Grau A, Kauffmann R, Kelley M, McCaffrey R, Hewitt K (2024). Cost containment analysis of superparamagnetic iron oxide (SPIO) injection in patients with ductal carcinoma in situ. Breast Cancer Res Treat. (Read full publication)
    4. Piltin MA, Norwood P, Ladores V, Mukhtar RA, Sauder CA, Golshan M, Tchou J, Rao R, Lee MC, Son J, Reyna C, Hewitt K, Kuerer H, Ahrendt G, Greenwalt I, Tseng J, Postlewait L, Howard-McNatt M, Jaskowiak N, Esserman LJ, Boughey JC, ISPY2 Locoregional Working Group (2024). Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial. Ann Surg Oncol. (Read full publication)
    5. Addae JK, Sweeting RS, Meszoely IM, McCaffrey RL, Kauffmann RM, Kelley MC, Grau AM, Hewitt K (2023). Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience. Breast Cancer Res Treat, 204(1), 117-121. (Read full publication)
    6. Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA (2023). Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial. Ann Surg Oncol, 30(11), 6401-6410. (Read full publication)
    7. Hewitt KC, Miller P, Piper M, Prionas N, Son JD, Alvarado M, Esserman LJ, Wong JM, Ewing C, Mukhtar RA (2021). Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies. Am J Surg, 223(4), 699-704. (Read full publication)
    8. Son JD, Piper M, Hewitt K, Alvarado M, Esserman LJ, Ewing C, Wong JM, Mukhtar RA (2020). Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience. Ann Surg Oncol, 28(5), 2555-2560. (Read full publication)
    9. Hewitt K, Son J, Glencer A, Borowsky AD, Cooperberg MR, Esserman LJ (2020). The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. Cancer Epidemiol Biomarkers Prev, 29(12), 2463-2474. (Read full publication)
    10. Hewitt K, Lin H, Faraklas I, Morris S, Cochran A, Saffle J (2013). Use of methylnaltrexone to induce laxation in acutely injured patients with burns and necrotizing soft-tissue infections. J Burn Care Res, 35(2), e106-11. (Read full publication)
    11. Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ (2013). Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure. HPB (Oxford), 16(1), 62-9. (Read full publication)

    Letter

    1. Scaife CL, Hewitt K, Sheng X, Russell KW, Mone MC (2015). Reply: Should we operate for an intraabdominal emergency in the setting of disseminated cancer? [Letter to the editor]. Surgery, 159(3), 981-3. (Read full publication)
    2. Scaife CL, Hewitt K, Sheng X, Russell KW, Mone MC (2015). Should we operate for an intra-abdominal emergency in the setting of disseminated cancer? [Letter to the editor]. Surgery, 158(3), 636-45. (Read full publication)